Close

More on LCTX

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-33.3% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (5/9/24)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Lineage Cell Therapeutics (NY:LCTX)
Delayed: 1.10 -0.04 (3.51%)
Prev. Close $1.14  
Open$1.15 
52 Wk High$ 
52 Wk Low$ 
Day High$1.15 
Day Low$1.10 
P/E N/A  
EPS$ 
Volume743,876 

Friends, Peers and Foes (?): BTIM, SYBX VIR (more...)

Apr 1, 2024 08:00 AM Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
Mar 18, 2024 08:00 AM Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
Mar 13, 2024 08:00 AM RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
Mar 11, 2024 08:01 AM RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
Mar 7, 2024 05:23 PM Lineage Cell Therapeutics (LCTX) Files $300M Mixed Shelf
Mar 7, 2024 04:01 PM Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Feb 29, 2024 08:00 AM Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
Feb 13, 2024 08:01 AM Lineage (LCTX) Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
Feb 13, 2024 08:00 AM Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
Feb 9, 2024 09:15 AM Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
View All Articles

Entities mentioned with LCTX

View All Entities